Investor Overview

Corporate Profile

Investor Highlights

Corporate Profile

Read Now
Corporate Profile

Investor Presentation

Read Now

Our Pipeline

Learn More
  • Price
  • Change

  • Copyright West LLC.
    Minimum 15 minutes delayed.
Recent Releases

Recent Releases

June 19, 2019

BeiGene Announces Updated Results from Two Ongoing Clinical Trials of Zanubrutinib in Patients with Mantle Cell Lymphoma in Presentations at the 15th International Conference on Malignant Lymphoma (ICML)

June 18, 2019

BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor

June 17, 2019

BeiGene Regains Full Global Rights to Its Investigational Anti-PD-1 Antibody Tislelizumab

Key Metrics

Key Metrics

  • 2,400


  • 800+

    Clinical team

  • 4


This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.